Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) announced its key role in a groundbreaking study published in Nature Genetics that successfully resolved a complex rare Mendelian condition using their advanced sequencing technology. The research, conducted in collaboration with the University of Washington and the Undiagnosed Diseases Network, utilized PacBio's Revio™ sequencing system to analyze a 9-month-old patient with bilateral retinoblastomas and developmental delays.
The study employed PacBio's synchronized Fiber-seq and Kinnex multiomic approach, which uniquely integrated long-read genomic, transcriptomic, methylomic, and epigenomic data in a single analysis. This comprehensive approach identified a chromosome X;13 balanced translocation affecting four key genes, each through different molecular mechanisms - a discovery that previous diagnostic methods, including short-read sequencing, failed to detect.
PacBio (NASDAQ: PACB) has announced that the Global Institute for Food Security (GIFS) at the University of Saskatchewan has become Canada's first Revio PacBio Certified Service Provider (CSP). GIFS will offer PacBio's HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform.
The certification ensures that GIFS has demonstrated the necessary capability, expertise, and infrastructure to deliver high-quality PacBio sequencing solutions, including genome assemblies, transcriptomics, and epigenetics. GIFS' OPAL platform provides comprehensive genomics solutions with automation, bioinformatics, and advanced data analysis capabilities.
This partnership aims to provide Canadian researchers and global clients access to highly accurate long-read sequencing data for various applications, from agricultural innovation to disease discovery.
PacBio (NASDAQ: PACB) and Radboud University Medical Center announced significant results from a study published in the American Journal of Human Genetics, demonstrating the effectiveness of PacBio's HiFi long-read sequencing technology in rare disease diagnostics. The study analyzed 100 challenging patient samples, achieving a 93% identification rate of pathogenic variants previously difficult to detect using short-read methods.
Key operational metrics include nearly 1,000 samples processed as of January 10, 2025, with 862 fully analyzed since August 2024. The collaboration has implemented automated library preparation for 24 samples per run, with plans to scale to 96 samples. Radboudumc has expanded its Revio instrument fleet to support 5,000 genomes using SPRQ chemistry, with first-tier diagnostic rollout targeted for summer 2025.
PacBio (NASDAQ: PACB) reported preliminary Q4 2024 revenue of $39.2 million and full-year 2024 revenue of $154.0 million, representing year-over-year declines of 33% and 23% respectively. The company shipped 23 Revio and 7 Vega sequencing systems in Q4, with instrument revenue at $15.3 million, down from $35.1 million in Q4 2023.
Notable developments include the early launch of the Vega benchtop system and SPRQ chemistry introduction, enabling sub-$500 HiFi genome sequencing on the Revio system. Consumables revenue remained stable at $18.8 million, with Revio achieving approximately $240,000 in annualized pull-through. The company strengthened its balance sheet by restructuring $459 million in convertible notes and ended 2024 with approximately $390 million in cash and investments.
PacBio (NASDAQ: PACB) and Intus Bio have launched GutID, the first commercial gut health test powered by HiFi sequencing technology. The at-home test combines Intus Bio's Titan-1 platform and PacBio's sequencing capabilities to provide comprehensive microbiome analysis with strain-level resolution.
GutID allows users to collect samples at home and receive detailed reports showing bacteria abundance, including both commensals and pathogens, along with a proprietary microbiome health score and personalized wellness recommendations. The test is particularly beneficial for individuals with IBS, IBD, and those focused on longevity.
This breakthrough addresses limitations of previous microbiome tests that offered low resolution and variable results. The microbiome has been linked to various health outcomes, including cancer, autoimmune, neurodegenerative, and chronic diseases. GutID is now available for purchase at www.gutid.com.
PacBio (NASDAQ: PACB) has delivered its first Vega systems to Berry Genomics under an early access agreement from 2022. Berry Genomics will develop targeted assays for carrier, prenatal, and newborn screening programs in China and other markets using the Vega platform.
The company will pursue NMPA regulatory review in China and support additional product registrations in other markets. Berry has committed to purchasing over 50 Vega units as part of the agreement.
Vega, PacBio's first benchtop long-read sequencing platform introduced last year, is designed as a compact, lower-throughput version of their Revio™ system. It offers HiFi technology for high accuracy and quick turnaround time, targeting small to medium-sized laboratories that need efficient genomics equipment with a smaller footprint and price tag.
PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California.
Interested parties can access a live webcast of the event through PacBio's investors page at investor.pacificbiosciences.com. The presentation recording will remain available for a minimum of 30 days after the event.
PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in four major upcoming investor conferences in November and December 2024. The schedule includes appearances at the UBS Global Healthcare Conference in Rancho Palos Verdes, Wolfe Research Healthcare Conference and Piper Sandler Healthcare Conference in New York, and Stephens Annual Investment Conference in Nashville. All presentations will be available via live webcasts on PacBio's investor page, with replays accessible for at least 30 days after each event.
PacBio reported Q3 2024 financial results with revenue of $40.0 million, down from $55.7 million in Q3 2023. Instrument revenue was $16.8 million, including 22 Revio systems sold. The company reported a net loss of $60.7 million ($0.22 per share). Notable developments include the announcement of SPRQ chemistry for Revio, increasing throughput by 33%, and the launch of Vega, a new long-read benchtop sequencer priced at $169,000. Cash position stood at $471.1 million as of September 30, 2024. The company also announced a private convertible note exchange transaction of $459 million.
PacBio announced a private convertible exchange transaction involving $459 million of its 1.50% Convertible Senior Notes due 2028. In exchange, the company will issue $200 million in new 1.50% Convertible Senior Notes due 2029, issue 20,451,570 shares of common stock, and make a $50 million cash payment. The new notes will have an initial conversion rate of 204.5157 shares per $1,000 principal amount, equivalent to approximately $4.89 per share. The transaction is expected to close around November 21, 2024, and will result in no remaining 2028 Notes outstanding.